530 related articles for article (PubMed ID: 30712900)
1. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.
Cholesterol Treatment Trialists' Collaboration
Lancet; 2019 Feb; 393(10170):407-415. PubMed ID: 30712900
[TBL] [Abstract][Full Text] [Related]
2. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.
; Mihaylova B; Emberson J; Blackwell L; Keech A; Simes J; Barnes EH; Voysey M; Gray A; Collins R; Baigent C
Lancet; 2012 Aug; 380(9841):581-90. PubMed ID: 22607822
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
; Baigent C; Blackwell L; Emberson J; Holland LE; Reith C; Bhala N; Peto R; Barnes EH; Keech A; Simes J; Collins R
Lancet; 2010 Nov; 376(9753):1670-81. PubMed ID: 21067804
[TBL] [Abstract][Full Text] [Related]
4. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.
; Herrington WG; Emberson J; Mihaylova B; Blackwell L; Reith C; Solbu MD; Mark PB; Fellström B; Jardine AG; Wanner C; Holdaas H; Fulcher J; Haynes R; Landray MJ; Keech A; Simes J; Collins R; Baigent C
Lancet Diabetes Endocrinol; 2016 Oct; 4(10):829-39. PubMed ID: 27477773
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials.
; Fulcher J; O'Connell R; Voysey M; Emberson J; Blackwell L; Mihaylova B; Simes J; Collins R; Kirby A; Colhoun H; Braunwald E; La Rosa J; Pedersen TR; Tonkin A; Davis B; Sleight P; Franzosi MG; Baigent C; Keech A
Lancet; 2015 Apr; 385(9976):1397-405. PubMed ID: 25579834
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.
Baigent C; Keech A; Kearney PM; Blackwell L; Buck G; Pollicino C; Kirby A; Sourjina T; Peto R; Collins R; Simes R;
Lancet; 2005 Oct; 366(9493):1267-78. PubMed ID: 16214597
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
; Kearney PM; Blackwell L; Collins R; Keech A; Simes J; Peto R; Armitage J; Baigent C
Lancet; 2008 Jan; 371(9607):117-25. PubMed ID: 18191683
[TBL] [Abstract][Full Text] [Related]
8. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis.
;
Lancet Diabetes Endocrinol; 2024 May; 12(5):306-319. PubMed ID: 38554713
[TBL] [Abstract][Full Text] [Related]
9. Interpretation of the evidence for the efficacy and safety of statin therapy.
Collins R; Reith C; Emberson J; Armitage J; Baigent C; Blackwell L; Blumenthal R; Danesh J; Smith GD; DeMets D; Evans S; Law M; MacMahon S; Martin S; Neal B; Poulter N; Preiss D; Ridker P; Roberts I; Rodgers A; Sandercock P; Schulz K; Sever P; Simes J; Smeeth L; Wald N; Yusuf S; Peto R
Lancet; 2016 Nov; 388(10059):2532-2561. PubMed ID: 27616593
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials.
Gencer B; Marston NA; Im K; Cannon CP; Sever P; Keech A; Braunwald E; Giugliano RP; Sabatine MS
Lancet; 2020 Nov; 396(10263):1637-1643. PubMed ID: 33186535
[TBL] [Abstract][Full Text] [Related]
11. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Baigent C; Landray MJ; Reith C; Emberson J; Wheeler DC; Tomson C; Wanner C; Krane V; Cass A; Craig J; Neal B; Jiang L; Hooi LS; Levin A; Agodoa L; Gaziano M; Kasiske B; Walker R; Massy ZA; Feldt-Rasmussen B; Krairittichai U; Ophascharoensuk V; Fellström B; Holdaas H; Tesar V; Wiecek A; Grobbee D; de Zeeuw D; Grönhagen-Riska C; Dasgupta T; Lewis D; Herrington W; Mafham M; Majoni W; Wallendszus K; Grimm R; Pedersen T; Tobert J; Armitage J; Baxter A; Bray C; Chen Y; Chen Z; Hill M; Knott C; Parish S; Simpson D; Sleight P; Young A; Collins R;
Lancet; 2011 Jun; 377(9784):2181-92. PubMed ID: 21663949
[TBL] [Abstract][Full Text] [Related]
12. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.
Cholesterol Treatment Trialists' Collaboration
Lancet; 2022 Sep; 400(10355):832-845. PubMed ID: 36049498
[TBL] [Abstract][Full Text] [Related]
13. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.
Collins R; Armitage J; Parish S; Sleigh P; Peto R;
Lancet; 2003 Jun; 361(9374):2005-16. PubMed ID: 12814710
[TBL] [Abstract][Full Text] [Related]
14. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.
Heart Protection Study Collaborative Group
Lancet; 2011 Dec; 378(9808):2013-2020. PubMed ID: 22115874
[TBL] [Abstract][Full Text] [Related]
15. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.
Heart Protection Study Collaborative Group
Lancet; 2002 Jul; 360(9326):7-22. PubMed ID: 12114036
[TBL] [Abstract][Full Text] [Related]
16. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy.
; Emberson JR; Kearney PM; Blackwell L; Newman C; Reith C; Bhala N; Holland L; Peto R; Keech A; Collins R; Simes J; Baigent C
PLoS One; 2012; 7(1):e29849. PubMed ID: 22276132
[TBL] [Abstract][Full Text] [Related]
17. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
[TBL] [Abstract][Full Text] [Related]
18. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
Marston NA; Giugliano RP; Im K; Silverman MG; O'Donoghue ML; Wiviott SD; Ference BA; Sabatine MS
Circulation; 2019 Oct; 140(16):1308-1317. PubMed ID: 31530008
[TBL] [Abstract][Full Text] [Related]
19. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
20. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.
Palmer SC; Navaneethan SD; Craig JC; Johnson DW; Perkovic V; Hegbrant J; Strippoli GF
Cochrane Database Syst Rev; 2014 May; (5):CD007784. PubMed ID: 24880031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
